Jaguar Health, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Jaguar Health, Inc. (JAGX) on June 27, 2025. The filing discloses the entry into material definitive agreements involving the exchange of royalty interests for newly issued Series M Perpetual Preferred Stock.
Key Financial Metrics and Transaction Details
The filing details two privately negotiated exchange agreements executed on June 27, 2025:
- Iliad Transaction: Issued 170 shares of Series M Preferred Stock to Iliad Research and Trading, L.P. in exchange for a $4,250,000 reduction in the outstanding balance of the October 2020 Royalty Interest.
- Streeterville Transaction: Issued 90 shares of Series M Preferred Stock to Streeterville Capital, LLC in exchange for a $2,250,000 reduction in the outstanding balance of the August 2022 Royalty Interest.
- Total Debt Reduction: The combined transactions reduced royalty interest obligations by $6,500,000.
- Preferred Stock Terms: Each share of Series M Preferred Stock has a stated value of $25,000. The stock accrues a preferred return of 10% per year for the first two years, 8% for years three and four, and 6% thereafter, payable in additional shares of Series M Preferred Stock.
The filing does not provide specific revenue, net income, operating cash flow, or total liquidity figures for the reporting period.
Material Changes and Structural Impacts
The primary material change is the conversion of $6.5 million in royalty debt into equity-like instruments (Series M Preferred Stock). This transaction alters the company's capital structure by:
- Reducing outstanding royalty liabilities.
- Creating a new class of preferred stock with senior liquidation rights over common stock.
- Imposing significant covenants on the company's ability to issue new equity, repay other indebtedness, or undergo fundamental transactions without the consent of Series M holders.
Outlook, Risks, and Management Commentary
Covenants and Restrictions: The Certificate of Designation imposes strict limitations on Jaguar Health, including:
- Equity Issuance Cap: The company cannot issue equity securities resulting in net proceeds exceeding $15 million (excluding ATM and exempt issuances) without holder consent.
- ATM Limit: Sales under the At-The-Market facility are capped at $10 million without consent.
- Debt Repayment: The company is prohibited from repaying outstanding indebtedness owed to the holders or their affiliates.
- Reverse Splits: Reverse stock splits require holder consent unless necessary to satisfy a Nasdaq deficiency notice.
Liquidity and Trading: There is no established trading market for the Series M Preferred Stock, and the company does not intend to list it. Liquidity for these shares is limited.
Default and Redemption: An "Event of Default" allows holders to force the redemption of all Series M shares for common stock. The redemption price includes the stated value, accrued preferred return, and other amounts, calculated based on the greater of the minimum price or a floor price of $0.542 per share.
Key Facts for Investor Verification
- Verify the remaining outstanding balance of the October 2020 and August 2022 Royalty Interests following the $6.5 million reduction.
- Confirm the current number of authorized and outstanding shares of Common Stock to assess the potential dilution impact of the Series M Preferred Stock exchange rights.
- Review the company's current cash position and liquidity to determine its ability to meet future royalty obligations or operational needs given the new covenants restricting equity raises.
- Monitor compliance with the 9.99% beneficial ownership cap for holders upon conversion or exchange of Series M shares.
- Check for any existing defaults under the secured promissory note to Streeterville (dated January 19, 2021), as this is a condition for exchanging Series M shares.